Tuberculosis Vaccines and Novel Drug Development
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".
Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 1692
Special Issue Editors
Interests: tuberculosis vaccines; tuberculosis chemotherapy and drug development; mycobacterium tuberculosis pathogenesis; host directed therapies; BCG induced trained immunity
Special Issues, Collections and Topics in MDPI journals
Interests: tuberculosis; mycobacteria; Interleukin-17; Th-17 cytokines; matrix metalloproteinase; intracellular signaling; microbiome; host immune response
Special Issue Information
Dear Colleagues,
Tuberculosis (TB) continues to be a major global health burden and kills over a million people annually. The emergence of drug-resistant strains has further worsened the situation that demands urgent need for vaccines and novel drug development against Mycobacterium tuberculosis (Mtb). The attenuated Mycobacterium bovis strain Bacille Calmette–Guerin (BCG) is the only FDA-licensed TB vaccine. BCG protects infants against disseminated TB, but it shows variable protection against adult pulmonary TB. Moreover, BCG can disseminate under immunosuppressed or immunocompromised conditions; hence, a safer and more efficacious TB vaccine is paramount. This requires a better understanding of the mechanisms that Mtb deploys to evade the host immune response.
Prolonged treatment regimens and poor drug compliance have led to the emergence of drug resistant strains and have thwarted international efforts to control this pandemic. A robust pipeline of new TB drug discovery and development is required for the successful development of new regimens. The recent second wave of anti-TB drug development that included Bedaquiline, Delamanid and Pretomanid offers the potential for shorter regimens and has been the driving force behind several translational studies and clinical trials in recent years. Finally, TB eradication programs suffered a major setback during the COVID-19 pandemic, and it is now time to join forces again in a concerted manner so that we can eradicate this scourge.
This Special Issue welcomes all types of manuscripts providing insight into aspects relevant to TB vaccines and novel drug development. We are interested in a wide scope of work including but not limited to basic science research and clinical studies. We welcome the submission of original articles, reviews and other research articles that will improve our knowledge in these areas.
Dr. Sangeeta Tiwari
Dr. Shivani Singh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis vaccine
- recombinant BCG
- BCG prime boost regimens
- drug-resistant TB
- second-line TB drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
